ADMAAdma Biologics, Inc.
Earnings
When Adma Biologics, Inc. reports, what it reported each quarter, and how the stock took the results.
64 quarters. Sep 30, 2010 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Feb 24, after the close
Wed, Feb 24, 2027in 99 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 25 – Mar 26
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $139.16M
- Revenue, change from a year earlier: Q3 2026 +5.1%, Q2 2026 +2.0%, Q1 2026 −0.3%, Q4 2025 +18.4%
- Net income
- $49.38M
- Net income, change from a year earlier: Q3 2026 +36.9%, Q2 2026 +10.5%, Q1 2026 +68.5%, Q4 2025 −55.9%
- EPS
- —
- EPS, change from a year earlier: Q3 2026 +46.7%, Q2 2026 +14.3%, Q1 2026 +72.7%, Q3 2025 ±0.0%
Latest results
- Revenue
- $141.10M
- +5.1%
- Net income
- $49.88M
- +36.9%
- EPS
- $0.22
- +46.7%
- Revenue
- $124.40M
- +2.0%
- Net income
- $37.82M
- +10.5%
- EPS
- $0.16
- +14.3%
- Revenue
- $114.49M
- −0.3%
- Net income
- $45.33M
- +68.5%
- EPS
- $0.19
- +72.7%
- Revenue
- $139.16M
- +18.4%
- Net income
- $49.38M
- −55.9%
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 4, 2026 · after-hours | Nov 4, 2026 | 35 d | 10-Q | $141.10M | +5.1% | $0.22 | +26.2% | |
| Q2 2026 | Jun 30, 2026 | Aug 5, 2026 · after-hours | Aug 5, 2026 | 36 d | 10-Q | $124.40M | +2.0% | $0.16 | +8.2% | |
| Q1 2026 | Mar 31, 2026 | May 6, 2026 · after-hours | May 6, 2026 | 36 d | 10-Q | $114.49M | −0.3% | $0.19 | 16.3% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Feb 25, 2026 · after-hours | Feb 25, 2026 | 56 d | 10-K | $139.16M | +18.4% | — | 3.5% | |
| Q3 2025 | Sep 30, 2025 | Nov 5, 2025 · after-hours | Nov 5, 2025 | 36 d | 10-Q | $134.22M | +12.0% | $0.15 | 8.7% | |
| Q2 2025 | Jun 30, 2025 | Aug 6, 2025 · after-hours | Aug 6, 2025 | 37 d | 10-Q | $121.98M | +13.8% | $0.14 | 9.8% | |
| Q1 2025 | Mar 31, 2025 | May 7, 2025 · after-hours | May 7, 2025 | 37 d | 10-Q | $114.80M | +40.2% | $0.11 | 10.2% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 3, 2025 · after-hours | Mar 18, 2025 | 77 d | 10-K | $117.55M | +59.1% | — | +7.3% | |
| Q3 2024 | Sep 30, 2024 | Nov 7, 2024 · after-hours | Nov 7, 2024 | 38 d | 10-Q | $119.84M | +78.1% | $0.15 | +14.8% | |
| Q2 2024 | Jun 30, 2024 | Aug 8, 2024 · after-hours | Aug 8, 2024 | 39 d | 10-Q | $107.19M | +78.3% | $0.13 | +30.9% | |
| Q1 2024 | Mar 31, 2024 | May 9, 2024 · after-hours | May 9, 2024 | 39 d | 10-Q | $81.88M | +43.9% | $0.08 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Feb 28, 2024 · after-hours | Feb 28, 2024 | 59 d | 10-K | $73.90M | +47.9% | — | 2.9% | |
| Q3 2023 | Sep 30, 2023 | Nov 8, 2023 · after-hours | Nov 8, 2023 | 39 d | 10-Q | $67.28M | +63.7% | $0.01 | +5.8% | |
| Q2 2023 | Jun 30, 2023 | Aug 9, 2023 · after-hours | Aug 9, 2023 | 40 d | 10-Q | $60.12M | +77.3% | -$0.03 | — | |
| Q1 2023 | Mar 31, 2023 | May 10, 2023 · after-hours | May 10, 2023 | 40 d | 10-Q | $56.91M | +95.6% | -$0.03 | +20.6% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 23, 2023 · after-hours | Mar 23, 2023 | 82 d | 10-K | $49.98M | +89.4% | — | — | |
| Q3 2022 | Sep 30, 2022 | Nov 9, 2022 · after-hours | Nov 9, 2022 | 40 d | 10-Q | $41.09M | +98.7% | -$0.08 | — | |
| Q2 2022 | Jun 30, 2022 | Aug 10, 2022 · after-hours | Aug 10, 2022 | 41 d | 10-Q | $33.91M | +90.2% | -$0.07 | — | |
| Q1 2022 | Mar 31, 2022 | May 11, 2022 · after-hours | May 11, 2022 | 41 d | 10-Q | $29.10M | +81.3% | -$0.13 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 24, 2022 · after-hours | Mar 24, 2022 | 83 d | 10-K | $26.38M | +89.0% | — | +17.3% | |
| Q3 2021 | Sep 30, 2021 | Nov 10, 2021 · after-hours | Nov 10, 2021 | 41 d | 10-Q | $20.68M | +101.2% | -$0.13 | +15.2% | |
| Q2 2021 | Jun 30, 2021 | Aug 11, 2021 · after-hours | Aug 11, 2021 | 42 d | 10-Q | $17.83M | +129.0% | -$0.15 | 2.6% | |
| Q1 2021 | Mar 31, 2021 | May 12, 2021 · after-hours | May 12, 2021 | 42 d | 10-Q | $16.05M | +57.3% | -$0.16 | +3.0% | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | Mar 25, 2021 · after-hours | Mar 25, 2021 | 84 d | 10-K | $13.96M | +15.9% | — | 11.7% | |
| Q3 2020 | Sep 30, 2020 | Nov 5, 2020 · after-hours | Nov 5, 2020 | 36 d | 10-Q | $10.28M | +42.3% | -$0.19 | 9.5% | |
| Q2 2020 | Jun 30, 2020 | Aug 5, 2020 · after-hours | Aug 5, 2020 | 36 d | 10-Q | $7.79M | +18.7% | -$0.23 | 19.7% | |
| Q1 2020 | Mar 31, 2020 | May 6, 2020 · after-hours | May 6, 2020 | 36 d | 10-Q | $10.20M | +189.1% | -$0.26 | 24.4% | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | Mar 12, 2020 · after-hours | Mar 13, 2020 | 73 d | 10-K | $12.04M | +196.7% | — | 16.6% | |
| Q3 2019 | Sep 30, 2019 | Nov 6, 2019 · after-hours | Nov 6, 2019 | 37 d | 10-Q | $7.22M | +70.7% | -$0.19 | 9.2% | |
| Q2 2019 | Jun 30, 2019 | Aug 7, 2019 · after-hours | Aug 8, 2019 | 39 d | 10-Q | $6.56M | +40.9% | -$0.25 | +8.8% | |
| Q1 2019 | Mar 31, 2019 | May 8, 2019 · after-hours | May 8, 2019 | 38 d | 10-Q | $3.53M | −12.7% | -$0.28 | 1.4% | |
| FY 2018 | ||||||||||
| Q4 2018 | Dec 31, 2018 | — | Mar 13, 2019 | 72 d | 10-K | $4.06M | −66.2% | -$0.39 | +1.0% | |
| Q3 2018 | Sep 30, 2018 | — | Nov 9, 2018 | 40 d | 10-Q | $4.23M | −10.6% | -$0.33 | — | |
| Q2 2018 | Jun 30, 2018 | — | Aug 10, 2018 | 41 d | 10-Q | $4.66M | +37.0% | -$0.35 | 3.7% | |
| Q1 2018 | Mar 31, 2018 | — | May 14, 2018 | 44 d | 10-Q | $4.04M | +53.8% | -$0.39 | — | |
| FY 2017 | ||||||||||
| Q4 2017derived | Dec 31, 2017 | — | Mar 29, 2018 | 88 d | 10-K | $12.00M | +260.7% | — | 4.6% | |
| Q3 2017 | Sep 30, 2017 | — | Nov 3, 2017 | 34 d | 10-Q | $4.73M | +61.0% | -$0.59 | 0.0% | |
| Q2 2017 | Jun 30, 2017 | — | Aug 11, 2017 | 42 d | 10-Q | $3.40M | +49.6% | -$0.55 | — | |
| Q1 2017 | Mar 31, 2017 | — | May 12, 2017 | 42 d | 10-Q | $2.63M | +23.8% | -$0.51 | 3.2% | |
| FY 2016 | ||||||||||
| Q4 2016derived | Dec 31, 2016 | — | Feb 24, 2017 | 55 d | 10-K | $3.33M | +32.5% | — | — | |
| Q3 2016 | Sep 30, 2016 | — | Nov 10, 2016 | 41 d | 10-Q | $2.94M | +58.6% | -$0.34 | — | |
| Q2 2016 | Jun 30, 2016 | — | Aug 12, 2016 | 43 d | 10-Q | $2.27M | +73.4% | -$0.50 | — | |
| Q1 2016 | Mar 31, 2016 | — | May 13, 2016 | 43 d | 10-Q | $2.12M | +41.3% | -$0.43 | — | |
| FY 2015 | ||||||||||
| Q4 2015derived | Dec 31, 2015 | — | Mar 23, 2016 | 83 d | 10-K | $2.51M | +68.7% | — | — | |
| Q3 2015 | Sep 30, 2015 | — | Nov 10, 2015 | 41 d | 10-Q | $1.85M | +35.6% | -$0.48 | +1.1% | |
| Q2 2015 | Jun 30, 2015 | — | Aug 11, 2015 | 42 d | 10-Q | $1.31M | −12.7% | -$0.44 | 0.1% | |
| Q1 2015 | Mar 31, 2015 | — | May 12, 2015 | 42 d | 10-Q | $1.50M | −3.7% | -$0.37 | — | |
| FY 2014 | ||||||||||
| Q4 2014derived | Dec 31, 2014 | — | Mar 9, 2015 | 68 d | 10-K | $1.49M | +251.1% | — | 17.6% | |
| Q3 2014 | Sep 30, 2014 | — | Nov 10, 2014 | 41 d | 10-Q | $1.37M | +23.4% | -$0.36 | — | |
| Q2 2014 | Jun 30, 2014 | — | Aug 11, 2014 | 42 d | 10-Q | $1.50M | +101.9% | -$0.43 | 0.0% | |
| Q1 2014 | Mar 31, 2014 | — | May 12, 2014 | 42 d | 10-Q | $1.56M | +96.8% | -$0.64 | +2.0% | |
| FY 2013 | ||||||||||
| Q4 2013derived | Dec 31, 2013 | — | Mar 28, 2014 | 87 d | 10-K | $424.03K | −19.0% | — | — | |
| Q3 2013 | Sep 30, 2013 | — | Nov 12, 2013 | 43 d | 10-Q | $1.11M | +207.3% | -$0.46 | +1.8% | |
| Q2 2013 | Jun 30, 2013 | — | Aug 12, 2013 | 43 d | 10-Q | $743.27K | +223.0% | -$0.83 | — | |
| Q1 2013 | Mar 31, 2013 | — | May 14, 2013 | 44 d | 10-Q | $792.94K | +17,921.3% | -$0.55 | — | |
| FY 2012 | ||||||||||
| Q4 2012derived | Dec 31, 2012 | — | Mar 6, 2013 | 65 d | 10-K | $523.28K | — | — | — | |
| Q3 2012 | Sep 30, 2012 | — | Nov 13, 2012 | 44 d | 10-Q | $360.34K | — | -$0.55 | — | |
| Q2 2012 | Jun 30, 2012 | — | Aug 14, 2012 | 45 d | 10-Q | $230.10K | — | -$0.20 | — | |
| Q1 2012 | Mar 31, 2012 | — | May 15, 2012 | 45 d | 10-Q | $4.40K | — | -$0.18 | — | |
| FY 2011 | ||||||||||
| Q4 2011 | Dec 31, 2011 | — | — | — | — | — | — | $0.00 | — | |
| Q3 2011 | Sep 30, 2011 | — | Oct 28, 2011 | 28 d | 10-Q | $0.00 | — | -$2.79 | — | |
| Q2 2011 | Jun 30, 2011 | — | — | — | — | — | — | -$6.79 | — | |
| Q1 2011 | Mar 31, 2011 | — | May 10, 2011 | 40 d | 10-Q | $0.00 | — | -$4.50 | — | |
| FY 2010 | ||||||||||
| Q3 2010 | Sep 30, 2010 | — | Oct 22, 2010 | 22 d | 10-Q | — | — | $0.00 | — | |
Earlier years, FY 2010 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR